Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. “2020 was a pivotal year for Kala, highlighted by U.S. Food and Drug Administration (FDA) approval of EYSUVIS, the first and only prescription therapy specifi

Full Story →